Loading...
WCLC congress 20242025-01-28T16:41:30+01:00

WCLC 2024

Lecture Board: Maximilian Hochmair, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from WCLC 2024

WCLC-2024

Full report (english)

EXPERT VIDEOS

All video interviews from WCLC 2024

Andrea R. Filippi talks about optimizing radiation and chemotherapy or immunotherapy combinations to improve efficacy and reduce side effects in locally advanced lung cancer. He addresses biomarkers guiding treatment, the importance of timing and sequencing, and differences between chemotherapy, immunotherapy, and targeted therapies, while highlighting promising trials and advancements for aimed at improving survival rates and quality of life for patients.

Pascale Tomasini discusses the most promising strategies currently being investigated to overcome resistance to PD-(L)1 inhibitors in advanced non-small cell lung cancer, highlights the results of the PIONeeR trial while addressing the ongoing challenges in developing and implementing precision immuno-oncology treatments for PD-(L)1-resistant NSCLC patients.

Diego Kauffmann-Guerrero provides insights into bispecific antibody treatments, an emerging class of therapeutics for small-cell lung cancer and neuroendocrine tumors of the lung. He highlights trials involving BiTEs in combination with other agents and offers an outlook on new treatment options for small-cell lung cancer expected to emerge in the coming years.

Gerrina Ruiter dives into the exciting world of HER2, exploring why it poses a tricky challenge in treating NSCLC, highlights the promising findings of the HER2 tyrosine kinase inhibitor zongertinib and shares insights on other notable innovations on the horizon in the field of HER2 inhibition.

Go to Top